¼¼°èÀÇ Å¸¾× äÃë ¹× Áø´Ü ½ÃÀå
Saliva Collection and Diagnostics
»óǰÄÚµå : 1777535
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 379 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,204,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,612,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

Ÿ¾× äÃë ¹× Áø´Ü ¼¼°è ½ÃÀåÀº 2030³â±îÁö 9¾ï 8,360¸¸ ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 7¾ï 9,450¸¸ ´Þ·¯·Î ÃßÁ¤µÇ´Â Ÿ¾× äÃë ¹× Áø´Ü ¼¼°è ½ÃÀåÀº 2030³â¿¡´Â 9¾ï 8,360¸¸ ´Þ·¯¿¡ ´ÞÇϰí, ºÐ¼® ±â°£ 2024-2030³â CAGRÀº 3.6%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ ±Í Çϼ± Ä÷º¼ÇÀº CAGR 3.4%¸¦ ±â·ÏÇÏ¸ç ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 5¾ï 5,540¸¸ ´Þ·¯¿¡ ´ÞÇÒ Àü¸ÁÀÔ´Ï´Ù. ¾ÇÇϼ±/¼³Çϼ± äÃë ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ µ¿¾È CAGR 4.3%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº ÃßÁ¤ 2¾ï 1,640¸¸ ´Þ·¯, Áß±¹Àº CAGR 6.7%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ Å¸¾× äÃë ¹× Áø´Ü ½ÃÀåÀº 2024³â¿¡ 2¾ï 1,640¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦ ´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 1¾ï 9,650¸¸ ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGRÀº 6.7%¸¦ ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖ°í, ºÐ¼® ±â°£ µ¿¾È CAGRÀº °¢°¢ 1.5%¿Í 2.8%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 2.1%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ Å¸¾× äÃë ¹× Áø´Ü ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

Ÿ¾× ±â¹Ý Áø´ÜÀÌ ÇコÄÉ¾î ¾÷°è¿¡¼­ Àα⸦ ²ø°í ÀÖ´Â ÀÌÀ¯´Â ¹«¾ùÀϱî?

Ÿ¾× äÃë ¹× Áø´ÜÀº ºñħ½ÀÀû ÀÇ·á °Ë»ç¿¡ º¯È­¸¦ °¡Á®¿ÔÀ¸¸ç, ±âÁ¸ÀÇ Ç÷¾× °Ë»ç¸¦ ´ëüÇÒ ¼ö ÀÖ´Â Æí¸®ÇÑ °Ë»ç ¹æ¹ýÀ» Á¦°øÇϰí ÀÖ½À´Ï´Ù. Ÿ¾× ±â¹Ý Áø´ÜÀº Áúº´ °¨Áö, À¯ÀüÀÚ °Ë»ç, È£¸£¸ó ºÐ¼®, ¾à¹° ¸ð´ÏÅ͸µ¿¡ Á¡Á¡ ´õ ¸¹ÀÌ »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. ƯÈ÷ COVID-19 »çÅ ÀÌÈÄ, ÀçÅà °Ë»ç¿Í ÇöÀå °Ë»ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϸ鼭 Ÿ¾× °Ë»ç ŰƮÀÇ Ã¤ÅÃÀÌ °¡¼ÓÈ­µÇ°í ÀÖ½À´Ï´Ù. ÀÌ °Ë»ç´Â ¹Ù´ÃÀ» Â Çʿ䰡 ¾ø±â ¶§¹®¿¡ ȯÀÚÀÇ ºÒÆíÇÔÀ» ÁÙÀÏ ¼ö ÀÖ°í, ¾î¸°ÀÌ, ³ëÀÎ, ¹Ù´Ã °øÆ÷ÁõÀÌ ÀÖ´Â »ç¶÷µé¿¡°Ô ´õ Ä£¼÷ÇÏ°Ô Áø´ÜÀ» ÇÒ ¼ö ÀÖ½À´Ï´Ù. »ý¸í°øÇÐÀÇ ¹ßÀüÀ¸·Î Ÿ¾×À» ÀÌ¿ëÇÑ Áø´Ü¹ýÀº ÇöÀç ¾Ï, °¨¿°, ½Å°æÁúȯ µîÀÇ Áúº´À» Á¶±â¿¡ ¹ß°ßÇÏ´Â µ¥ Ȱ¿ëµÇ°í ÀÖ½À´Ï´Ù. ½Å¼ÓÇÏ°í ºñħ½ÀÀûÀÎ Áø´Ü¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÔ¿¡ µû¶ó Ÿ¾× äÃë ¹× Áø´Ü ½ÃÀåÀÌ Å©°Ô ¼ºÀåÇϰí ÀÖ½À´Ï´Ù.

Ÿ¾× ±â¹Ý Áø´ÜÀ» °­È­ÇÏ´Â ±â¼ú Çõ½ÅÀº ¹«¾ùÀϱî?

ºÐÀÚ»ý¹°Çаú ¹ÙÀÌ¿À¼¾¼­ ±â¼úÀÇ ºñ¾àÀûÀÎ ¹ßÀüÀ¸·Î Ÿ¾× Áø´ÜÀÇ Á¤È®¼º°ú È¿À²¼ºÀÌ Çâ»óµÇ°í ÀÖ½À´Ï´Ù. PCR(ÁßÇÕÈ¿¼Ò ¿¬¼â ¹ÝÀÀ) ±â¹ÝÀÇ Å¸¾× °Ë»ç´Â ¹ÙÀÌ·¯½º ¹× ¼¼±Õ °¨¿°À» °í°¨µµ·Î °ËÃâÇÒ ¼ö ÀÖ½À´Ï´Ù. AI¸¦ Ȱ¿ëÇÑ µ¥ÀÌÅÍ ºÐ¼®°ú ·¦¿ÂĨ ±â¼úÀ» ÅëÇØ Ÿ¾×À» ÀÌ¿ëÇÑ À¯ÀüÀÚ °Ë»ç¸¦ °£¼ÒÈ­ÇÏ¿© º¸´Ù ºü¸£°í Á¤È®ÇÑ °á°ú¸¦ ¾òÀ» ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ¶ÇÇÑ Å¸¾× ³» ¹ÙÀÌ¿À¸¶Ä¿¸¦ Áö¼ÓÀûÀ¸·Î ¸ð´ÏÅ͸µÇÏ´Â ¿þ¾î·¯ºí ¹ÙÀÌ¿À¼¾¼­µµ µîÀåÇØ ħ½ÀÀû ½Ã¼ú ¾øÀ̵µ ½Ç½Ã°£ °Ç°­ ÃßÀûÀÌ °¡´ÉÇØÁ³½À´Ï´Ù. ¶ÇÇÑ, DNA¿Í RNAÀÇ ¹«°á¼ºÀ» À¯ÁöÇÏ´Â ¾ÈÁ¤È­ ¿ÏÃæ¾×°ú °°Àº Ÿ¾× äÃë ÀåÄ¡ÀÇ °³¼±À¸·Î Ÿ¾× »ùÇ÷ΠÁø´ÜÇÒ ¼ö ÀÖ´Â ÁúȯÀÇ ¹üÀ§°¡ ³Ð¾îÁö°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼ú Çõ½ÅÀ¸·Î Ÿ¾×À» ÀÌ¿ëÇÑ °Ë»ç´Â ¿¹¹æ ÀÇ·á¿Í ¸ÂÃãÇü ÀÇ·áÀÇ °­·ÂÇÑ µµ±¸°¡ µÇ°í ÀÖ½À´Ï´Ù.

Ÿ¾× äÃë ¹× Áø´Ü ¼ö¿ä¸¦ ÁÖµµÇÏ´Â ÇコÄÉ¾î ºÐ¾ß´Â?

ºñħ½ÀÀû Áø´Ü¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϸ鼭 °¨¿° °Ë»ç, À¯ÀüÀÚ °Ë»ç, ³»ºÐºñÇÐ, ¹ýÀÇÇÐ µî ´Ù¾çÇÑ ÇコÄÉ¾î ºÐ¾ß¿¡¼­ äÅÃÀÌ È®´ëµÇ°í ÀÖ½À´Ï´Ù. Á¦¾à ¾÷°è¿¡¼­´Â ¾à¹° °³¹ß ¹× ÀÓ»ó½ÃÇè¿¡ Ÿ¾× °Ë»ç¸¦ Ȱ¿ëÇϰí ÀÖÀ¸¸ç, ½ºÆ÷Ã÷ ÀÇÇÐ Àü¹®°¡µéÀº ¼±¼öµéÀÇ °æ±â·Â ¹× ȸº¹À» Æò°¡Çϱâ À§ÇØ Å¸¾× ±â¹Ý È£¸£¸ó ¸ð´ÏÅ͸µ¿¡ ÀÇÁ¸Çϰí ÀÖ½À´Ï´Ù. ¿ø°ÝÀÇ·á ¹× ÀçÅÃÀÇ·á ¼­ºñ½ºÀÇ Áõ°¡´Â ȯÀÚ°¡ º´¿øÀ» ¹æ¹®ÇÏÁö ¾Ê°íµµ »ùÇÃÀ» Á¦ÃâÇÒ ¼ö ÀÖ´Â ÀçÅà Ÿ¾× äÃë ŰƮÀÇ ¼ö¿ä¸¦ ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¹ýÀÇÇÐ ¹× ¹ý ÁýÇà ºÐ¾ß¿¡¼­´Â ¹üÁË ¼ö»ç ¹× ½Å¿ø È®Àο¡ Ÿ¾× ±â¹Ý DNA °Ë»ç¸¦ Ȱ¿ëÇÏ´Â »ç·Ê°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ´Ù¾çÇÑ ºÐ¾ß·ÎÀÇ Àû¿ëÀÌ È®´ëµÇ¸é¼­ Ÿ¾× Áø´ÜÀº ÇコÄɾîÀÇ ÁÖ·ù·Î ÀÚ¸® Àâ°í ÀÖ½À´Ï´Ù.

Ÿ¾× äÃë ¹× Áø´Ü ½ÃÀåÀÇ ¼ºÀåÀ» ÃËÁøÇÏ´Â ¿äÀÎÀº ¹«¾ùÀΰ¡?

ºñħ½ÀÀû °Ë»ç¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, ºÐÀÚÁø´ÜÀÇ ¹ßÀü, ¿ø°ÝÀÇ·á ¼­ºñ½º È®´ë µîÀÌ Å¸¾× äÃë ¹× Áø´Ü ½ÃÀåÀÇ ¼ºÀåÀ» °ßÀÎÇϰí ÀÖ½À´Ï´Ù. COVID-19 ÆÒµ¥¹ÍÀº ½Å¼ÓÇÑ ¹ÙÀÌ·¯½º °ËÃâÀ» À§ÇÑ Å¸¾× ±â¹Ý Áø´Ü¿¡ ´ëÇÑ ÅõÀÚ¸¦ °¡¼ÓÈ­Çϰí, º¸´Ù ±¤¹üÀ§ÇÑ Áúº´ °ËÁøÀÇ °¡´É¼ºÀ» ºÎ°¢½ÃÄ×½À´Ï´Ù. ¾Ï°ú ´ç´¢º´À» Æ÷ÇÔÇÑ ¸¸¼ºÁúȯÀÇ À¯º´·ü Áõ°¡µµ Ÿ¾× ±â¹Ý ¹ÙÀÌ¿À¸¶Ä¿ °ËÃâ ¿¬±¸¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¸ÂÃãÇü ÀÇ·áÀÇ ÃßÁøÀº Ÿ¾× »ùÇÃÀ» ÀÌ¿ëÇÑ À¯ÀüÀÚ ¹× ÈÄ»ýÀ¯ÀüÇÐÀû °Ë»çÀÇ Ã¤Åà Ȯ´ë·Î À̾îÁö°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Áúº´ÀÇ Á¶±â ¹ß°ß°ú Àú·ÅÇÑ °¡°ÝÀÇ Áø´ÜÀ» ÃËÁøÇϱâ À§ÇÑ Á¤ºÎÀÇ ³ë·Âµµ ½ÃÀå È®´ë¿¡ ÈûÀ» ½Ç¾îÁÖ°í ÀÖ½À´Ï´Ù. ±â¼úÀÇ ¹ßÀüÀÌ °è¼ÓµÇ´Â °¡¿îµ¥, Ÿ¾×À» ÀÌ¿ëÇÑ °Ë»ç´Â ¹Ì·¡ ÇコÄɾ¼­ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ºÎ¹®

äÃë ºÎÀ§(±ÍÇϼ± äÃë, ¾ÇÇϼ±¡¤¼³Çϼ± äÃë, ±âŸ), ¿ëµµ(Áúº´ Áø´Ü, ¹ýÀÇÇÐ ¿ëµµ, Á¶»ç), ÃÖÁ¾ ¿ëµµ(Ä¡°ú, Áø´Ü ¿¬±¸¼Ò, Á¦¾à¡¤¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â¾÷, ¿¬±¸±â°ü)

Á¶»ç ´ë»ó ±â¾÷ »ç·Ê

AI ÅëÇÕ

Global Industry Analysts´Â °ËÁõµÈ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI ÅøÀ» ÅëÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ Çõ½ÅÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â ÀϹÝÀûÀÎ LLM ¹× ¾÷°èº° SLM Äõ¸®¸¦ µû¸£´Â ´ë½Å ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾çÀÇ ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»ç ¼ÒÀçÁö, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±âÁØÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¸ÅÃâ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº Ç϶ô, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû, °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Saliva Collection and Diagnostics Market to Reach US$983.6 Million by 2030

The global market for Saliva Collection and Diagnostics estimated at US$794.5 Million in the year 2024, is expected to reach US$983.6 Million by 2030, growing at a CAGR of 3.6% over the analysis period 2024-2030. Parotid Gland Collection, one of the segments analyzed in the report, is expected to record a 3.4% CAGR and reach US$555.4 Million by the end of the analysis period. Growth in the Submandibular / Sublingual Gland Collection segment is estimated at 4.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$216.4 Million While China is Forecast to Grow at 6.7% CAGR

The Saliva Collection and Diagnostics market in the U.S. is estimated at US$216.4 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$196.5 Million by the year 2030 trailing a CAGR of 6.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.5% and 2.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.1% CAGR.

Global Saliva Collection and Diagnostics Market - Key Trends & Drivers Summarized

Why Is Saliva-Based Diagnostics Gaining Popularity In The Healthcare Industry?

Saliva collection and diagnostics are transforming non-invasive medical testing, offering a convenient alternative to traditional blood tests. Saliva-based diagnostics are increasingly being used for disease detection, genetic testing, hormone analysis, and drug monitoring. The growing demand for home-based and point-of-care testing, particularly following the COVID-19 pandemic, has accelerated the adoption of saliva testing kits. These tests eliminate the need for needles, reducing patient discomfort and making diagnostics more accessible for children, elderly individuals, and those with needle phobia. With advancements in biotechnology, saliva-based diagnostics are now being used for early disease detection, including cancer, infectious diseases, and neurological disorders. As the demand for rapid and non-invasive diagnostics increases, the saliva collection and diagnostics market is experiencing significant growth.

What Technological Innovations Are Enhancing Saliva-Based Diagnostics?

Breakthroughs in molecular biology and biosensor technology are improving the accuracy and efficiency of saliva diagnostics. PCR-based (polymerase chain reaction) saliva tests are enabling highly sensitive detection of viral and bacterial infections. AI-powered data analysis and lab-on-a-chip technology are streamlining saliva-based genetic testing, allowing for faster and more precise results. Wearable biosensors that continuously monitor biomarkers in saliva are also emerging, providing real-time health tracking without invasive procedures. Additionally, improvements in saliva collection devices, such as stabilization buffers that preserve DNA and RNA integrity, are expanding the range of conditions that can be diagnosed using saliva samples. These innovations are making saliva-based testing a powerful tool for preventive and personalized medicine.

Which Healthcare Sectors Are Driving The Demand For Saliva Collection And Diagnostics?

The growing need for non-invasive diagnostics is driving adoption across multiple healthcare sectors, including infectious disease testing, genetic screening, endocrinology, and forensic science. The pharmaceutical industry is using saliva testing for drug development and clinical trials, while sports medicine professionals rely on saliva-based hormone monitoring to assess athlete performance and recovery. The rise of telemedicine and home healthcare services is further fueling demand for at-home saliva collection kits, enabling patients to submit samples without visiting a clinic. Additionally, the forensic and law enforcement sectors are increasingly using saliva-based DNA testing for criminal investigations and identity verification. With applications expanding across various fields, saliva diagnostics is becoming a mainstream healthcare solution.

What Factors Are Fueling The Growth Of The Saliva Collection And Diagnostics Market?

The growth in the saliva collection and diagnostics market is driven by rising demand for non-invasive testing, advancements in molecular diagnostics, and the expansion of telehealth services. The COVID-19 pandemic accelerated investment in saliva-based diagnostics for rapid viral detection, highlighting their potential for broader disease screening. The increasing prevalence of chronic diseases, including cancer and diabetes, is also driving research into saliva-based biomarker detection. The push for personalized medicine is leading to greater adoption of genetic and epigenetic testing using saliva samples. Additionally, government initiatives promoting early disease detection and affordable diagnostics are supporting market expansion. As technology continues to improve, saliva-based testing is expected to play a pivotal role in the future of healthcare.

SCOPE OF STUDY:

The report analyzes the Saliva Collection and Diagnostics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Collection Site (Parotid Gland Collection, Submandibular / Sublingual Gland Collection, Others); Application (Disease Diagnostics, Forensic Applications, Research); End-Use (Dentistry, Diagnostic Laboratories, Pharma & Biotech Companies, Research Institutes)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 43 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â